842TiPNal-iri/lv5-fu versus paclitaxel as second-line...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

842TiPNal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Randrian, V, Adenis, A, Desrame, J, Barbier, E, Di Fiore, F, Lievre, A, Dahan, L, Laurent-Puig, P, Mineur, L, Breysacher, G, Roquin, G, Louafi, S, Lopez, A, Louvet, C, Borg, C, Metges, J-P, Faroux, R,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz247.168
Date:
October, 2019
File:
PDF, 84 KB
2019
Conversion to is in progress
Conversion to is failed